scholarly journals Molecular Basis for Lipid Specificity of the Coagulation Factor X Membrane-Binding Domain

2016 ◽  
Vol 110 (3) ◽  
pp. 424a
Author(s):  
Melanie P. Muller ◽  
Emad Tajkhorshid
2017 ◽  
Vol 15 (10) ◽  
pp. 2005-2016 ◽  
Author(s):  
M. P. Muller ◽  
Y. Wang ◽  
J. H. Morrissey ◽  
E. Tajkhorshid

2020 ◽  
Author(s):  
Usha Pallabi Kar ◽  
Himani Dey ◽  
Abdur Rahaman

ABSTRACTDynamins are large cytoplasmic GTPases that are targeted to specific cellular membranes which they remodel via membrane fusion or fission. Although the mechanism of target membrane selection by dynamins has been studied, the molecular basis of conferring specificity to bind specific lipids on the target membranes is not known in any of the family members. Here, we report a mechanism of nuclear membrane recruitment of Drp6 that is involved in nuclear remodeling in Tetrahymena thermophila. Recruitment of Drp6 depends on a domain that binds to cardiolipin-rich bilayers. Consistent with this, the nuclear localization of wildtype Drp6 was inhibited by depleting cardiolipin in the cell. Cardiolipin binding was blocked with a single amino acid substitution (I553M) in the membrane-binding domain of Drp6. Importantly, the I553M substitution was sufficient to block nuclear localization without affecting other properties of Drp6. Consistent with this result, co-expression of wildtype Drp6 was sufficient to rescue the localization defect of I553M variant in Tetrahymena. Inhibition of cardiolipin synthesis or perturbation in Drp6 recruitment to nuclear membrane caused defects in the formation of new macronuclei post-conjugation. Taken together, our results elucidate a molecular basis of target membrane selection by a nuclear dynamin, and establish the importance of a defined membrane-binding domain and its target lipid in facilitating nuclear expansion.


2017 ◽  
Vol 112 (3) ◽  
pp. 479a
Author(s):  
Melanie Muller ◽  
Emad Tajkhorshid

1974 ◽  
Vol 31 (01) ◽  
pp. 040-051 ◽  
Author(s):  
Gustav Gaudernack ◽  
Åse Gladhaug Berre ◽  
Bjarne Østerud ◽  
Hans Prydz

SummaryMonospecific antisera against the human coagulation factor X have been raised in rabbits by injections of purified antigen. Such antiserum was used to study the cross-reacting material without factor X activity which is present in the blood of warfarin-treated patients and animals as well as to study the changes in factor X during coagulation. One patient with congenital factor X deficiency was also studied.A complete identity was found between factor X in Macaca mulatta and human blood. During warfarin treatment antigenically cross-reacting material appeared in plasma. This was not adsorbed on BaSO4, and inhibited the coagulation activity of normal factor X.Both this material, normal factor X and the cross-reacting material in plasma from a patient congenitally deficient in factor X gave rise to split products during coagulation by the intrinsic pathway, i. e. all of them served as substrates for the intrinsic activator of factor X.


1996 ◽  
Vol 75 (02) ◽  
pp. 313-317 ◽  
Author(s):  
D J Kim ◽  
A Girolami ◽  
H L James

SummaryNaturally occurring plasma factor XFriuli (pFXFr) is marginally activated by both the extrinsic and intrinsic coagulation pathways and has impaired catalytic potential. These studies were initiated to obtain confirmation that this molecule is multi-functionally defective due to the substitution of Ser for Pro at position 343 in the catalytic domain. By the Nelson-Long site-directed mutagenesis procedure a construct of cDNA in pRc/CMV was derived for recombinant factor XFriuli (rFXFr) produced in human embryonic (293) kidney cells. The rFXFr was purified and shown to have a molecular size identical to that of normal plasma factor X (pFX) by gel electrophoretic, and amino-terminal sequencing revealed normal processing cleavages. Using recombinant normal plasma factor X (rFXN) as a reference, the post-translational y-carboxy-glutamic acid (Gla) and (β-hydroxy aspartic acid (β-OH-Asp) content of rFXFr was over 85% and close to 100%, respectively, of expected levels. The specific activities of rFXFr in activation and catalytic assays were the same as those of pFXFr. Molecular modeling suggested the involvement of a new H-bond between the side-chains of Ser-343 and Thr-318 as they occur in anti-parallel (3-pleated sheets near the substrate-binding pocket of pFXFr. These results support the conclusion that the observed mutation in pFXFr is responsible for its dysfunctional activation and catalytic potentials, and that it accounts for the moderate bleeding tendency in the homozygous individuals who possess this variant procoagulant.


1982 ◽  
Vol 47 (02) ◽  
pp. 096-100 ◽  
Author(s):  
K Mertens ◽  
R M Bertina

SummaryThe intrinsic activation of human factor X has been studied in a system consisting of purified factors and in plasma. In both these systems factor Xa stimulated the activation of factor X by factor IXa plus factor VIII This is due to the activation of factor VIII by factor Xa. When this factor Xa is formed via the extrinsic pathway, the extrinsic factor X activator functions as a stimulator of the intrinsic factor X activator.


2021 ◽  
pp. 102570
Author(s):  
Mariana Ebert ◽  
Elmar Raquet ◽  
Sabine Schweisgut ◽  
Peter M. Schmidt ◽  
Thomas Weimer

Sign in / Sign up

Export Citation Format

Share Document